This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Genentech’s Ocrevus (ocrelizumab) to treat patients with multiple sclerosis with a neurologist
Ticker(s): RHHBYWho's the expert?
Institution: WUSTL
- Associate Professor of Neurology and Director of Multiple Sclerosis Clinic at WUSTL.
- Currently treats 450 patients with Multiple Sclerosis (Dedicated MS specialist).
- Has prescribed Tecfidera to 75 patients and Vumerity to 10 patients.
- Extensive MS investigator clinical trial experience.
Interview GoalThe conversation will focus on the data from the Phase III OCARINA II trial evaluating Genentech’s Ocrevus® (ocrelizumab) as a twice a year 10-minute subcutaneous injection to treat patients with relapsing forms of MS or primary progressive MS (RMS or PPMS).
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
